Edition:
United Kingdom

Esperion Announces Positive Top-Line Results From Phase 2 Study Of Bempedoic Acid Added-On To A PCSK9 Inhibitor


Tuesday, 27 Mar 2018 

March 27 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA.ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT WITH 30% ADDITIONAL LDL-C LOWERING.ESPERION THERAPEUTICS INC - BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR OBSERVED TO BE SAFE AND WELL-TOLERATED IN THIS STUDY.ESPERION THERAPEUTICS - TO SUBMIT NDAS TO U.S. FDA FOR BEMPEDOIC ACID, BEMPEDOIC ACID/EZETIMIBE COMBINATION PILL FOR LDL-C-LOWERING INDICATIONS BY Q1 2019. 

Related Company News

Company Quote

36.87
-7.10543E-15 -0.00%
23 Aug 2019